Tokyo-headquartered pharmaceutical company, Astellas announced that an additional indication for nateglinide, has been recently approved in Japan, according to Ildong Pharm.
Nateglinide is a fast-acting postprandial hypoglycemic agent for use in combination therapy. It was developed by the Astellas along with another Japanese pharma company, Ajinomoto.
Ildong plans to file a local applica...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.